This is a news story, published by , that relates primarily to Novo Nordisk's news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from , you can click here:
more news fromOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
novo nordisk. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest financepharmaceuticals news, reuters best news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
experimental drug amycretinReutersagency
•
81% Informative
Early trial data for Novo Nordisk's experimental drug amycretin showed participants had a weight loss of 13.1% after 12 weeks .
Shares surged more than 8% to record highs, shooting the company up in global rankings to the 12th most valuable company from 14 previously.
VR Score
78
Informative language
78
Neutral language
47
Article tone
formal
Language
English
Language complexity
77
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links